Marshall Wace
CTNM

Marshall Wace’s Contineum Therapeutics CTNM Stock Holding History

Marshall Wace’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
118,058
-108,244
-48% -$1.42M ﹤0.01% 1882
2026
Q1 		$2.96M Buy
226,302
+45,498
+25% +$610K ﹤0.01% 1573
2025
Q4 		$2.07M Sell
180,804
-12,687
-7% -$145K ﹤0.01% 1565
2025
Q3 		$2.27M Buy
193,491
+164,806
+575% +$1.33M ﹤0.01% 1553
2025
Q2 		$114K Sell
28,685
-2,399
-8% -$10.4K ﹤0.01% 2529
2025
Q1 		$217K Buy
31,084
+20,248
+187% +$184K ﹤0.01% 2377
2024
Q4 		$159K Buy
+10,836
New +$172K ﹤0.01% 2390

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's CTNM Position: Q2 2026 in Review

Marshall Wace reduced its Contineum Therapeutics (CTNM) stake by 48% in Q2 2026, selling an estimated $1.42M and leaving 118,058 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

Marshall Wace first reported a position in CTNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.96M in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Marshall Wace held 118,058 shares of Contineum Therapeutics worth $1.93M as of Q2 2026.
  • Marshall Wace sold 108,244 Contineum Therapeutics shares in Q2 2026, an estimated $1.42M.
  • Contineum Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1882 holding.
  • Marshall Wace first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Marshall Wace's Contineum Therapeutics position peaked at $2.96M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.